Lupus Nephritis Class III-IV, +/- V research hub

An adaptive, randomized, double-blind, dose exploration, parallel group, placebo controlled, multicenter phase 2 trial to evaluate the efficacy, safety and tolerability of LNP023 in combination with standard-of-care with and without oral corticosteroids in adult patients with active lupus nephritis Class III-IV, +/- V

This study looks at a new drug called iptacopan (LNP023) for adults with lupus nephritis, a kidney problem caused by lupus. Researchers want to see if adding it to usual care helps heal the kidneys, cuts down lupus flare-ups, and lowers the need for strong steroid medications.